Home » UCB SAYS INTERESTED IN ELI LILLY'S BELGIAN R&D SITE

UCB SAYS INTERESTED IN ELI LILLY'S BELGIAN R&D SITE

July 3, 2006

Belgian pharmaceutical company UCB SA said Monday it may be interested in Eli Lilly & Co.'s (LLY) research and development center at Mont-Saint-Guibert in Belgium.
Easy Bourse

KEYWORDS FDAnews Drug Daily Bulletin

08Sep
Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections
13Sep
Trial Master File Inspection Readiness: From Chaos to Calm
14Sep
Omnichannel Engagement: Are You Digitally Ready?
15Sep
Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis
20Sep
Building a World-Class Pharmaceutical Advertising and Promotion Review Program
21Sep
The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

UCB SAYS INTERESTED IN ELI LILLY'S BELGIAN R&D SITE

Upcoming Events

Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

Trial Master File Inspection Readiness: From Chaos to Calm

Omnichannel Engagement: Are You Digitally Ready?

Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

Building a World-Class Pharmaceutical Advertising and Promotion Review Program

The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

Featured Products

FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

Guardant Health Receives FDA Approval for Guardant360 CDx Liquid Biopsy Test

Genentech Inks Licensing Deal With Jemincare Over Androgen Receptor Degrader

FDA Clears Thermo Fisher Scientific’s Wheat and Sesame Allergy Tests

The Revised ICH E8: A Guide to New Clinical Trial Requirements